Published in Vaccine Weekly, December 6th, 2000
They point out that for an HIV vaccine to be useful across a number of geographic regions, it will need to exhibit such interclade immune responses.
F. Verrier et al. reported "strong immunochemical cross-reactivity with V3 peptides from clades B, C, and F" in patients who had been immunized with recombinant canarypox virus vCP205 and recombinant gp120(SF2). Antibodies in blood samples exhibited weaker activity against a number of V3 peptides from clades A, D, G, and H, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.